PCN116 Economic Impact of First-Line (1L) Immunotherapies in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR)
Dec 1, 2020, 00:00
10.1016/j.jval.2020.08.253
https://www.valueinhealthjournal.com/article/S1098-3015(20)32509-2/fulltext
Title :
PCN116 Economic Impact of First-Line (1L) Immunotherapies in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)32509-2&doi=10.1016/j.jval.2020.08.253
First page :
Section Title :
Open access? :
No
Section Order :
10200